← Leaderboards
Sheryl F. Kelsey
University Of Pittsburgh At Pittsburgh
$8,354,235
Attributed
$8,354,235
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.1M · FY2005–11$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$30,419,806 · 5
By mechanism
U01$28,981,732 · 3
P50$1,300,934 · 1
R03$137,140 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Michael S. Diamond$85,358,908
- Mary L Marazita$48,708,804
- Surinder Kumar Batra$34,830,369
- Pat R Levitt$42,762,313
- Stephen A Murray$43,730,323
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationFollow-UpCoronaryMyocardial InfarctionMortality Vital StatisticsReportingDatabasesEventManuscriptsInterviewData ManagementIschemiaSafetyTranslatingMyocardial Ischemia /HypoxiaMedicalCoronary ArteriosclerosisGene ExpressionClinical Research SiteDesignCardiovascular Disorder DiagnosisDiagnosis Design /EvaluationHormone Regulation /Control MechanismHuman Data
Grant awards (21)
Dynamic Evaluation of Coronary Intervention Renewal: Drug-Eluting Stents$742,170
U01 · FY2011 · HL · contact PI
Dynamic Evaluation of Coronary Intervention Renewal: Drug-Eluting Stents$732,168
U01 · FY2010 · HL · contact PI
BARI II: A TRIAL OF REVASC. & GLYCEMIC CONTROL IN NIDDM$1,129,551
U01 · FY2009 · HL · contact PI
Dynamic Evaluation of Coronary Intervention Renewal: Drug-Eluting Stents$753,041
U01 · FY2009 · HL · contact PI
Cardiovascular Events in Women's Ischemia Syndrome Evaluation$61,783
R03 · FY2009 · AG · contact PI
BARI II: A TRIAL OF REVASC. & GLYCEMIC CONTROL IN NIDDM$1,740,456
U01 · FY2008 · HL · contact PI
Dynamic Evaluation of Coronary Intervention Renewal: Drug-Eluting Stents$748,083
U01 · FY2008 · HL · contact PI
Core--Biostatistics and Data Management$224,756
P50 · FY2008 · HL · contact PI
Cardiovascular Events in Women's Ischemia Syndrome Evaluation$75,357
R03 · FY2008 · AG · contact PI
BARI II: A TRIAL OF REVASC. & GLYCEMIC CONTROL IN NIDDM$2,646,947
U01 · FY2007 · HL · contact PI
Core--Biostatistics and Data Management$232,179
P50 · FY2007 · HL · contact PI
BARI II: A TRIAL OF REVASC. & GLYCEMIC CONTROL IN NIDDM$8,776,719
U01 · FY2006 · HL · contact PI
Core C--Biostatistics and Data Management$283,438
P50 · FY2006 · HL · contact PI
BARI II: A TRIAL OF REVASC. &GLYCEMIC CONTROL IN NIDDM$7,771,898
U01 · FY2005 · HL
Women's Ischemia Syndrome Evaluation$630,764
U01 · FY2005 · HL
Core C--Biostatistics and Data Management$277,114
P50 · FY2005 · HL
Women's Ischemia Syndrome Evaluation$803,512
U01 · FY2004 · HL
Core C--Biostatistics and Data Management$283,447
P50 · FY2004 · HL
Women's Ischemia Syndrome Evaluation$810,057
U01 · FY2003 · HL
Women's Ischemia Syndrome Evaluation$842,543
U01 · FY2002 · HL
Women's Ischemia Syndrome Evaluation$853,823
U01 · FY2001 · HL